CircuLite: Treating Heart Failure’s Lost Patients
Executive Summary
Even with all of the advances and options in heart failure therapy, there remain no real options for a large number of patients who are seriously ill but not yet at the end-stage of the disease. CircuLite hopes to change that with a partial support device for patients who don’t need a VAD.
You may also be interested in...
Tug Of War In The LVAD Market
With the rivalry between Thoratec and HeartWare intensifying in the LVAD space, all eyes are now on recent strategic acquisitions by both companies, as well as ongoing clinical studies and next-generation devices in the pipeline.
HeartWare Adds Synergy Circulatory Support System With $30 Mil. CircuLite Buy
The acquisition could significantly expand the targeted market base for HeartWare, but first the company will need to re-launch CircuLite’s Synergy in Europe, which experiences a design problem the first time around.
Two Small Companies See Huge Opportunities In Heart Failure Device Space
CardioKinetix, maker of a unique, percutaneously placed ventricular partitioning device, and CircuLite, which is developing a less invasive cardiac assist device, are moving into US clinical trials with their technologies – an important milestone for emerging companies in the difficult heart failure space. Both offer therapies aimed at helping fill the huge heart failure treatment gap that exists today.